A systematic review of definitions and reporting of bleeding outcome measures in haemophilia

被引:23
作者
Chai-Adisaksopha, C. [1 ,2 ]
Hillis, C. [1 ]
Thabane, L. [2 ,3 ]
Iorio, A. [1 ,2 ]
机构
[1] McMaster Univ, Dept Med, Hamilton, ON, Canada
[2] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
[3] St Josephs Healthcare Hamilton, Biostat Unit, Hamilton, ON, Canada
关键词
haemarthrosis; haemophilia A; haemophilia B; haemorrhage; review; RECOMBINANT FACTOR VIIA; FC FUSION PROTEIN; SECONDARY PROPHYLAXIS; EFFICACY; SAFETY; SURVEILLANCE; PHASE-3; RISK;
D O I
10.1111/hae.12750
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionBleeding frequency is an important outcome commonly used in haemophilia studies. There is a variation in practice in how bleeding is measured and defined. AimThe primary objective of this study was to determine how investigators define and report bleeding outcome measures. MethodsMEDLINE, EMBASE and the CENTRAL were searched from January 1990 to January 2014. We retrieved all published studies that included patients with haemophilia A or B and reported some measures of bleeding. Two reviewers independently performed title and abstract screening, full-text review and data abstraction of the identified studies. ResultsA total of 118 studies fulfilled the inclusion criteria. Study designs were randomized controlled trials (RCT; 14%), cohort (68%), cross-sectional (5%) and others design (11%). The median duration of follow-up (Q1, Q3) was 20 (7.9, 50) months. We found 10 different bleeding outcomes reported [absolute number of bleeding 60 (50.8%) studies, annualized bleeding rate 60 (50.8%) studies, bleed per month 10 (8.5%) studies and others 11 (9.3%) studies]. Of these, 32 (27%) studies reported only mean or median without dispersion and 33 (28%) studies did not report any measures of central tendency (dispersion). ConclusionsThere is substantial variation in definitions and measures of bleeding outcomes in the haemophilia literature. This creates difficulty and limitations in comparing the outcomes between studies and in performing meta-analysis. The haemophilia research community needs to develop a consensus on a clear definition of bleeding and how to address the limitations associated with variations in measures of bleeding between centres and studies.
引用
收藏
页码:731 / 735
页数:5
相关论文
共 13 条
  • [1] Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels
    den Uijl, I. E. M.
    Fischer, K.
    van der Bom, J. G.
    Grobbee, D. E.
    Rosendaal, F. R.
    Plug, I.
    [J]. HAEMOPHILIA, 2011, 17 (01) : 41 - 44
  • [2] Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials
    Fischer, K.
    Collins, P.
    Bjorkman, S.
    Blanchette, V.
    Oh, M.
    Fritsch, S.
    Schroth, P.
    Spotts, G.
    Ewenstein, B.
    [J]. HAEMOPHILIA, 2011, 17 (03) : 433 - 438
  • [3] The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
    Higgins, Julian P. T.
    Altman, Douglas G.
    Gotzsche, Peter C.
    Jueni, Peter
    Moher, David
    Oxman, Andrew D.
    Savovic, Jelena
    Schulz, Kenneth F.
    Weeks, Laura
    Sterne, Jonathan A. C.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2011, 343
  • [4] Long-standing prophylactic therapy vs. episodic treatment in young people with severe haemophilia: a comparison of age-matched Danish and Russian patients
    Ingerslev, J.
    Lethagen, S.
    Poulsen, L. Hvitfeldt
    Sorensen, B.
    Lopatina, E.
    Tentsova, I.
    Yastrubinetskaya, O.
    Plyushch, O. P.
    [J]. HAEMOPHILIA, 2014, 20 (01) : 58 - 64
  • [5] Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors
    Konkle, B. A.
    Ebbesen, L. S.
    Erhardtsen, E.
    Bianco, R. P.
    Lissitchkov, T.
    Rusen, L.
    Serban, M. A.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (09) : 1904 - 1913
  • [6] Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS
    Lalezari, S.
    Martinowitz, U.
    Windyga, J.
    Enriquez, M. M.
    Delesen, H.
    Schwartz, L.
    Scharrer, I.
    [J]. HAEMOPHILIA, 2014, 20 (01) : E15 - E22
  • [7] Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
    Mahlangu, Johnny
    Powell, Jerry S.
    Ragni, Margaret V.
    Chowdary, Pratima
    Josephson, Neil C.
    Pabinger, Ingrid
    Hanabusa, Hideji
    Gupta, Naresh
    Kulkarni, Roshni
    Fogarty, Patrick
    Perry, David
    Shapiro, Amy
    Pasi, K. John
    Apte, Shashikant
    Nestorov, Ivan
    Jiang, Haiyan
    Li, Shuanglian
    Neelakantan, Srividya
    Cristiano, Lynda M.
    Goyal, Jaya
    Sommer, Jurg M.
    Dumont, Jennifer A.
    Dodd, Nigel
    Nugent, Karen
    Vigliani, Gloria
    Luk, Alvin
    Brennan, Aoife
    Pierce, Glenn F.
    [J]. BLOOD, 2014, 123 (03) : 317 - 325
  • [8] Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice
    Oldenburg, J.
    Goudemand, J.
    Valentino, L.
    Richards, M.
    Luu, H.
    Kriukov, A.
    Gajek, H.
    Spotts, G.
    Ewenstein, B.
    [J]. HAEMOPHILIA, 2010, 16 (06) : 866 - 877
  • [9] Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients
    Powell, Jerry
    Martinowitz, Uri
    Windyga, Jerzy
    Di Minno, Giovanni
    Hellmann, Andrzej
    Pabinger, Ingrid
    Enriquez, Monika Maas
    Schwartz, Lawrence
    Ingerslev, Jorgen
    Pabinger-Fasching, I.
    Hermans, C.
    Poon, M.C.
    Ritchie, B.
    Tinmouth, A.
    Teitel, J.
    Zupancic-Salek, S.
    Ingerslev J, J.
    Chambos H, H.
    Schved, J.F.
    Guillet, B
    Oldenburg, J.
    Klamroth, R.
    Martinowitz, U.
    Di Minno, Matteo Nicola Dario
    Santagostino, E.
    Schinco, P.
    Musso, R.
    Morfini, M.
    Rocin, A.
    Meijer, K.
    Larosvan, B.
    Holme, P.
    Windyga, J.
    Skotnicki, A.
    Hellmann, A.
    Zawilska, K.
    Robak, T.
    Soto, I.
    Haya, S.
    Kavakli, K.
    Antmen, B.
    Yesilipek, M.A.
    Hay, C.
    Wilde, J.
    Rangarajan, S.
    Bernstein, J.
    Damon, L.
    Gill, J.
    Gruppo, R.
    Cuker, A.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2012, 108 (05) : 913 - 922
  • [10] Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
    Powell, Jerry S.
    Pasi, K. John
    Ragni, Margaret V.
    Ozelo, Margareth C.
    Valentino, Leonard A.
    Mahlangu, Johnny N.
    Josephson, Neil C.
    Perry, David
    Manco-Johnson, Marilyn J.
    Apte, Shashikant
    Baker, Ross I.
    Chan, Godfrey C.
    Novitzky, Nicolas
    Wong, Raymond S.
    Krassova, Snejana
    Allen, Geoffrey
    Jiang, Haiyan
    Innes, Alison
    Li, Shuanglian
    Cristiano, Lynda M.
    Goyal, Jaya
    Sommer, Jurg M.
    Dumont, Jennifer A.
    Nugent, Karen
    Vigliani, Gloria
    Brennan, Aoife
    Luk, Alvin
    Pierce, Glenn F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (24) : 2313 - 2323